€1.45 Billion Boost! GSK and CureVac Forge New Path in mRNA Vaccines

GSK takes the lead on promising influenza and COVID-19 vaccines in a revamped collaboration with CureVac. The new licensing deal grants GSK full control over development, manufacturing, and global sales of these mRNA vaccine candidates.CureVac gets a financial boost with a €400 million upfront payment and potential for over €1 billion more in milestones and royalties. This agreement allows CureVac to focus on its own pipeline while still benefiting from the progress of the partnered vaccines.

Both companies see promise in the collaboration's potential to deliver best-in-class vaccines. GSK will leverage its expertise to accelerate development, while CureVac retains the rights to its broader mRNA technology portfolio.

The legalese: The deal awaits standard regulatory approvals before finalization.